CN1143116A - New human erythropoietin - Google Patents
New human erythropoietin Download PDFInfo
- Publication number
- CN1143116A CN1143116A CN 96115004 CN96115004A CN1143116A CN 1143116 A CN1143116 A CN 1143116A CN 96115004 CN96115004 CN 96115004 CN 96115004 A CN96115004 A CN 96115004A CN 1143116 A CN1143116 A CN 1143116A
- Authority
- CN
- China
- Prior art keywords
- erythropoietin
- plasmid
- cell
- pdhfr
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 title claims abstract description 9
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 title claims abstract description 9
- 102000044890 human EPO Human genes 0.000 title claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 30
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 46
- 102000003951 Erythropoietin Human genes 0.000 claims description 44
- 108090000394 Erythropoietin Proteins 0.000 claims description 44
- 229940105423 erythropoietin Drugs 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 claims description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 abstract description 7
- 239000002299 complementary DNA Substances 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000015806 constitutional megaloblastic anemia with severe neurologic disease Diseases 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 16
- 238000013467 fragmentation Methods 0.000 description 9
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 7
- 230000035800 maturation Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 101150002621 EPO gene Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 101150074155 DHFR gene Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The geneclone and expression in cell of mammal of human erythropoietin features that the total RNA extracted is reversely transcribed to synthesize the first chain of cDNA and then cloned via polymerase chain reaction to obtain DNA segment of coded human erythropoietin, and the said DNA segement is connected with expression carrier PCR III to obtain recombination plasmid pE/C, which, together with plasmid pDHFR, is transfected to ovarium cell of Chinese hamstser of dihydrofolate reductase deficiency to obtain the cell strain expressing human erythropoietin. The cell strain of the present invention has the features of stable passage and high expression amount.
Description
The present invention relates to a kind of erythropoietin technical field, a kind of gene clone of erythropoietin specifically and the method for in mammalian cell, expressing thereof.
(Erythropoietin EPO) is a kind of important hemopoieticgrowth factor to erythropoietin, and in vivo, it can stimulate propagation, the differentiation of red corpuscle precursor cell in the marrow specifically, increases sophisticated red corpuscle from the burst size of marrow to peripheral blood.Kidney is the main generation position of erythropoietin in the human body of growing up, and the generation minimizing of the erythropoietin that causes because of renal failure can cause anaemia.Erythropoietin has been used for the treatment of clinically anaemia that renal failure causes, patient AIDS because of anaemia due to the zidovudine treatment and tumour patient because of the anaemia due to the chemotherapy, in operation and bone marrow transplantation, erythropoietin also is well used.Behind epo treatment, pcv and hemoglobin level obviously raise in the patient body, and the dependency of transfusing blood is obviously reduced, and therefore, the clinical application of erythropoietin prospect is very wide.
The natural human erythropoietin mainly is to extract from anaemia patients'blood or urine, and is very limited because of its source, can't satisfy the heavy demand of clinical and scientific research.The development of recombinant DNA technology is for the mass production erythropoietin provides a new approach.Since 1985, existing many scholars have successfully expressed erythropoietin (Fu-kuen, Lin etc., Proc.Natl. Acad.Sci.USA, 82:7580-7584,1985 in mammalian cell; Kenneth Jacobs etc., Nature, 313:806-810,1985; Jerry S.Powell etc., Proc.Natl.Acad.Sci.USA, 83:6465-6469,1986; Huang Liwen etc., Chinese science B collects, 24:178-184,1994).These genetically engineered erythropoietins of expressing in mammalian cell have in the body identical with the natural human erythropoietin, external activity.Following method is mainly followed in the gene clone and the expression in mammalian cell thereof of genetically engineered erythropoietin at present.
1. the acquisition of the dna fragmentation of coding erythropoietin: mainly contain the dna fragmentation that dual mode obtains the coding erythropoietin.A kind of is to extract tire liver chromosomal DNA, is primer then with the specific oligonucleotide, goes out the gene fragment of erythropoietin through PCR amplification, carries out external splicing then.Another kind is to extract people's tire liver mRNA, through the synthetic cDNA library of reverse transcription.Or screening people tire liver gene group library, the gene of the erythropoietin that obtains encoding downcuts human epo gene and is connected with expression vector, imports mammalian cell, extraction mRNA, and another mistake is transcribed into the cDNA library.Screening cDNA library, the dna fragmentation of the erythropoietin that obtains encoding.
2. the dna fragmentation of coding erythropoietin is connected with expression vector.Expression vector commonly used has pDSVL, pSV2, and these two kinds of plasmids have Tetrahydrofolate dehydrogenase (dhfr) gene, also can use pDll, do not contain the dhfr gene.
3. the structure of cell strain: recombinant plasmid is imported mammalian cell, obtain needed cell strain through screening.Host cell commonly used is COS cell and Chinese hamster ovary celI.
According to the document of having delivered, the genomic constitution of Chinese's erythropoietin is identical with the document of abroad delivering with the aminoacid sequence of structure and erythropoietin.193 amino acid of EPO gene coding region codified, wherein preceding 27 amino acid are formed the targeting signal peptide, and all the other 166 amino acid are formed maturation protein, and its molecular weight is 18399D.The recombinant epo molecule is because of degree of glycosylation and sugared type composition difference, and its molecular weight does not wait from 26KD to 34KD.
The invention provides a kind of new erythropoietin and production method thereof, this production method comprises the structure of recombinant DNA carrier, with recombinant vectors DNA transfection mammalian cell, and culturing cell, purifying obtains a kind of new erythropoietin from supernatant.
The present invention also provides a kind of new dna molecular of the erythropoietin of encoding.The 418th bit base of this dna molecular is C, and the document of having delivered is G.
The present invention also provides a kind of amino acid composition sequence of new erythropoietin.This sequence is made up of 193 amino acid, and wherein preceding 27 amino acid are formed signal peptide, and back 166 amino acid are formed maturation protein, and the 113rd amino acids of maturation protein is Arg, rather than Gly.Through the sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, apparent molecular weight is 36～45KD, is a glycoprotein.The derivative of erythropoietin of the present invention is also included among the present invention.
The present invention also provides a kind of recombinant DNA molecules.The dna fragmentation of coding erythropoietin is connected with expression vector pCRIII, obtains recombinant plasmid pE/C.
The present invention also provides the mammalian cell that is used for the expressing human erythropoietin.With plasmid pE/C and pDHFR cotransfection Chinese hamster ovary cell, obtain the engineering cell strain of express recombinant erythropoietin, its expression amount surpasses 10000U/ml10
6Cell is 2～3 times of existing cell strain expression amount.
The present invention also provides and has contained a kind of new erythropoietin and the medicine of derivative thereof, and erythropoietin of the present invention and derivative thereof are as all or part of active constituent of medicine in this medicine.
The present invention also provides a kind of new erythropoietin has been used for the method for disease treatment, contains this new people's cell and generates plain medicine and can be used for treating the renal failure anaemia, and anaemia due to the chemotherapy of tumors is also as the bone marrow transplantation toughener.Realize that technical essential of the present invention is:
1. from fresh Chinese's tire liver, extract total RNA,, amplify the dna fragmentation of coding Chinese erythropoietin again through polymerase chain reaction (PCR) through first chain of the synthetic cDNA of reverse transcription.
2. the DNA product with amplification is connected with expression vector pCRIII, connects the competent cell that product is used for transformed into escherichia coli DH5 α, through screening, evaluation, obtains recombinant molecule pE/C.
3. adopt United States Biochemical, the sequence of the dna fragmentation of coding Chinese erythropoietin among the Inc. Sequenase kit measurement plasmid pE/C.Sequencing result shows that coding region the 418th bit base is C, and the 113rd amino acids of the maturation protein of deriving thus is Arg.
4. recombinant plasmid pE/C and plasmid pDHFR (available from Invitrogen) are adopted the Chinese hamster ovary cell (CHO dhfr-) of lipofection cotransfection Tetrahydrofolate dehydrogenase defective type, pressurization screening in the ever-increasing methotrexate of concentration (MTX) is after resulting cell strain is confirmed in enzyme immunoassay.
The invention will be further described below by embodiment
1. the structure of recombinant plasmid pE/C
Extract total RNA from 1 gram Chinese tire liver, 1.2% agarose electrophoresis shows that 18S and 28S RNA are complete.Getting the total RNA of 5ug is template, first chain with the synthetic cDNA of avian myeloblastosis virus reverse transcriptase (AMV-RT), this synthetic product is got 1ul as template by dilution in 1: 10, with specific oligonucleotide as 3 '-end and 5 '-the end primer, as archaeal dna polymerase, amplify the dna fragmentation of coding Chinese erythropoietin with the Tag enzyme through polymerase chain reaction (PCR).The PCR reaction conditions is: 95 ℃ of sex change 10 minutes, and cycle stage 95 ℃ of sex change 45 seconds, 56 ℃ of annealing 50 seconds, 72 ℃ were extended 2 minutes, extended 10 minutes at 72 ℃ after 35 circulations.The PCR product shows that through 1% agarose electrophoresis amplified production is about 630bp, and is consistent with the expection size.Reclaim the 630bp fragment from agarose, be connected at 12 ℃ with carrier pCRIII and spend the night, ligase enzyme is the T4 dna ligase.Connect product and be used for transformed into escherichia coli DH5 α competent cell.Picking list colony inoculation in the 5ml substratum, 37 ℃ of overnight incubation.Prepare plasmid DNA in a small amount, through E
CORI digestion show that recombinant plasmid contains the 630bp fragment, and direction of insertion is correct.The plasmid called after pE/C that obtains, its structure is seen accompanying drawing 1, its complete sequence sees Table 1..
The full DNA sequence Sequence Range:1 to 6079 of table 1. plasmid pE/C
* * * * *
GACGGATCGG?GAGATCTCCC?GATCCCCTAT?GGTCGACTCT?CAGTACAATC
100
* * * * *
TGCTCTGATG?CCGCATAGTT?AAGCCAGTAT?CTGCTCCCTG?CTTGTGTGTT
* * * * *
GGAGGTCGCT?GAGTAGTGCG?CGAGCAAAAT?TTAAGCTACA?ACAAGGCAAG
200
* * * * *
GCTTGACCGA?CAATTGCATG?AAGAATCTGC?TTAGGGTTAG?GCGTTTTGCG
* * * * *
CTGCTTCGCG?ATGTACGGGC?CAGATATACG?CGTTGACATT?GATTATTGAC
300
* * * * *
TAGTTATTAA?TAGTAATCAA?TTACGGGGTC?ATTAGTTCAT?AGCCCATATA
* * * * *
TGGAGTTCCG?CGTTACATAA?CTTACGGTAA?ATGGCCCGCC?TGGCTGACCG
400
* * * * *
CCCAACGACC?CCCGCCCATT?GACGTCAATA?ATCACGTATG?TTCCCATAGT
* * * * *
AACGCCAATA?GGGACTTTCC?ATTGACGTCA?ATGGGTGGAC?TATTTACGGT
500
* * * * *
AAACTGCCCA?CTTGGCAGTA?CATCAAGTGT?ATCATATGCC?AAGTACGCCC
* * * * *
CCTATTGACG?TCAATGACGG?TAAATGGCCC?GCCTGGCATT?ATGCCCAGTA
600
* * * * *
CATGACCTTA?TGGGACTTTC?CTACTTGGCA?GTACATCTAC?GTATTAGTCA
* * * * *
TCGCTATTAC?CATGGTGATG?CGGTTTTGGC?AGTACATCAA?TGGGCGTGGA
700
* * * * *
TAGCGGTTTG?ACTCACGGGG?ATTTCCAAGT?CTCCACCCCA?TTGACGTCAA
* * * * *
TGGGAGTTTG?TTTTGGCAGC?AAAATCAACG?GGACTFTCCA?AAATGTCGTA
800
* * * * *ACAACTCCGC?CCCATTGACG?CAAATGGGCG?GTAGGCGTGT?ACGGTGGGAG
* * * * *GTGTATATAA?GCAGAGCTCT?CTGGCTAACT?AGAGAACCCG?CTGCTTAACT
900
* * * * *GGCTTATCGA?AATTAATACG?ACTCACTATA?GGGAGACCCA?AGCTTGAGAT
* * * * *GGGGGTGCAC?GAATGTCCTG?CCTGGCTGTG?GCTTCTCCTG?TCCCTGCTGT
1000
* * * * *CGCTCCCTCT?GGGCCTCCCA?GTCCTGGGCG?CCCCACCACG?CCTCATCTGT
* * * * * GACAGCCGAG?TCCTGGAGAG?GTACCTCTTG?GAGGCCAAGG?AGGCCGAGAA
1100
* * * * *TATCACGACG?GGCTGTGCTG?AACACTGCAG?CTTGAATGAG?AATATCACTG
* * * * *TCCCAGACAC?CAAAGTTAAT?TTCTATGCCT?GGAAGAGGAT?GGAGGTCGGG
1200
* * * * *CAGCAGGCCG?TAGAAGTCTG?GCAGGGCCTG?GCCCTGCTGT?CGGAAGCTGT
* * * * *CCTGCGGGGC?CAGGCCCTGT?TGGTCAACTC?TTCCCAGCCG?TGGGAGCCCC
1300
* * * * *TGCAGCTGCA?TGTGGATAAA?GCCGTCAGTG?GCCTTCGCAG?CCTCACCACT
* * * * *CTGCTTCGGG?CTCTGCGAGC?CCAGAAGGAA?GCCATCTCCC?CTCCAGATGC
1400
* * * * * GGCCTCAGCT?GCTCCACTCC?GAACAATCAC?TGCTGACACT?TTCCGCAAAC
* * * * *TCTTCCGAGT?CTACTCCAAT?TTCCTCCGGG?GAAAGCTGAA?GCTGTACACA
1500
* * * * *GGGGAGGCCT?GCAGGACAGG?GGACAGATGA?CCAGGTGTGT?CCACCTGGGC
* * * * *ATACTTAAGG?ACGTCGGGCC?CCCTAGGTGA?TCAAGATCTA?GAGGGCCCTA
1600
* * * * *TTCTATAGTG?TCACCTAAAT?GCTAGAGCTC?GCTGATCAGC?CTCGACTGTG
* * * * *CCTTCTAGTT?GCCAGCCATC?TGTTGTTTGC?CCCTCCCCCG?TGCCTTCCTT
1700
* * * * *GACCCTGGAA?GGTGCCACTC?CCACTGTCCT?TTCCTAATAA?AATGAGGAAA
* * * * *TTGCATCGCA?TTGTCTGAGT?AGGTGTCATT?CTATTCTGGG?GGGTGGGGTG
1800
* * * * *GGGCAGGACA?GCAAGGGGGA?GGATTGGGAA?GACAATAGCA?GGCATGCTGG
* * * * *GGATGCGGTG?GGCTCTATGG?AACCAGCTGG?GGCTCGAGGG?GGGATCCCCA
1900
* * * * *CGCGCCCTGT?AGCGGCGCAT?TAAGCGCGGC?GGGTGTGGTG?GTTACGCGCA
* * * * *GCGTGACCGC?TACACTTGCC?AGCGCCCTAG?CGCCCGCTCC?TTTCGCTTTC
2000
* * * * *TTCCCTTCCT?TTCTCGCCAC?GTTCGCCGGC?TTTCCCCGTC?AAGCTCTAAA
* * * * *TCGGGGCATC?CCTTTAGGGT?TCCGATTTAG?TGCTTTACGG?CACCTCGACC
2100
* * * * *CCAAAAAACT?TGATTAGGGT?GATGGTTCAC?GTAGTGGGCC?ATCGCCCTGA
* * * * *TAGACGGTTT?TTCGCCCTTT?GACGTTGGAG?TCCACGTTCT?TTAATAGTGG
2200
* * * * *ACTCTTGTTC?CAAACTGGAA?CAACACTCAA?CCCTATCTCG?GTCTATTCTT
* * * * *TTGATTTATA?AGGGATTTTG?GGGATTTCGG?CCTATTGGTT?AAAAAATGAG
2300
* * * * *CTGATTTAAC?AAAAATTTAA?CGCGAATTTT?AACAAAATAT?TAACGTTTAC
* * * * *AATTTAAATA?TTTGCTTATA?CAATCTTCCT?GTTTTTGGGG?CTTTTCTGAT
2400
* * * * *TATCAACCGG?GGTGGGTACC?GAGCTCGAAT?TCTGTGGAAT?GTGTGTCAGT
* * * * *TAGGGTGTGG?AAAGTCCCCA?GGCTCCCCAG?GCAGGCAGAA?GTATGCAAAG
2500
* * * * *CATGCATCTC?AATTAGTCAG?CAACCAGGTG?TGGAAAGTCC?CCAGGCTCCC
* * * * *CAGCAGGCAG?AAGTATGCAA?AGCATGCATC?TCAATTAGTC?AGCAACCATA
2600
* * * * *GTCCCGCCCC?TAACTCCGCC?CATCCCGCCC?CTAACTCCGC?CCAGTTCCGC
* * * * *CCATTCTCCG?CCCCATGGCT?GACTAATTTT?TTTTATTTAT?GCAGAGGCCG
2700
* * * * *AGGCCGCCTC?GGCCTCTGAG?CTATTCCAGA?AGTAGTGAGG?AGGCTTTTTT
* * * * *GGAGGCCTAG?GCTTTTGCAA?AAAGCTCCCG?GGAGCTTGGA?TATCCATTTT
2800
* * * * *CGGATCTGAT?CAAGAGACAG?GATGAGGATC?GTTTCGCATG?ATTGAACAAG
* * * * *ATGGATTGCA?CGCAGGTTCT?CCGGCCGCTT?GGGTGGAGAG?GCTATTCGGC
2900
* * * * *TATGACTGGG?CACAACAGAC?AATCGGCTGC?TCTGATGCCG?CCGTGTTCCG
* * * * *GCTGTCAGCG?CAGGGGCGCC?CGGTTCTTTT?TGTCAAGACC?GACCTGTCCG
3000
* * * * *GTGCCCTGAA?TGAACTGCAG?GACGAGGCAG?CGCGGCTATC?GTGGCTGGCC
* * * * *ACGACGGGCG?TTCCTTGCGC?AGCTGTGCTC?GACGTTGTCA?CTGAAGCGGG
3100
* * * * *AAGGGACTGG?CTGCTATTGG?GCGAAGTGCC?GGGGCAGGAT?CTCCTGTCAT
* * * * *CTCACCTTGC?TCCTGCCGAG?AAAGTATCCA?TCATGGCTGA?TGCAATGCGG
3200
* * * * *CGGCTGCATA?CGCTTGATCC?GGCTACCTGC?CCATTCGACC?ACCAAGCGAA
* * * * *ACATCGCATC?GAGCGAGCAC?GTACTCGGAT?GGAAGCCGGT?CTTGTCGATC
3300
* * * * *AGGATGATCT?GGACGAAGAG?CATCAGGGGC?TCGCGCCAGC?CGAACTGTTC
* * * * *GCCAGGCTCA?AGGCGCGCAT?GCCCGACGGC?GAGGATCTCG?TCGTGACCCA
3400
* * * * *TGGCGATGCC?TGCTTGCCGA?ATATCATGGT?GGAAAATGGC?CGCTTTTCTG
* * * * *GATTCATCGA?CTGTGGCCGG?CTGGGTGTGG?CGGACCGCTA?TCAGGACATA
3500
* * * * *GCGTTGGCTA?CCCGTGATAT?TGCTGAAGAG?CTTGGCGGCG?AATGGGCTGA
* * * * *CCGCTTCCTC?GTGCTTTACG?GTATCGCCGC?TCCCGATTCG?CAGCGCATCG
3600
* * * * *CCTTCTATCG?CCTTCTTGAC?GAGTTCTTCT?GAGCGGGACT?CTGGGGTTCG
* * * * *AAATGACCGA?CCAAGCGACG?CCCAACCTGC?CATCACGAGA?TTTCGATTCC
3700
* * * * *ACCGCCGCCT?TCTATGAAAG?GTTGGGCTTC?GGAATCGTTT?TCCGGGACGC
* * * * *CGGCTGGATG?ATCCTCCAGC?GCGGGGATCT?CATGCTGGAG?TTCTTCGCCC
3800
* * * * *ACCCCAACTT?GTTTATTGCA?GCTTATAATG?GTTACAAATA?AAGCAATAGC
* * * * *ATCACAAATT?TCACAAATAA?AGCATTTTTT?TCACTGCATT?CTAGTTGTGG
3900
* * * * *TTTGTCCAAA?CTCATCAATG?TATCTTATCA?TGTCTGGATC?CCGTCGACCT
* * * * *CGAGAGCTTG?GCGTAATCAT?GGTCATAGCT?GTTTCCTGTG?TGAAATTGTT
4000
* * * * *ATCCGCTCAC?AATTCCACAC?AACATACGAG?CCGGAAGCAT?AAAGTGTAAA
* * * * *GCCTGGGGTG?CCTAATGAGT?GAGCTAACTC?ACATTAATTG?CGTTGCGCTC
4100
* * * * *ACTGCCCGCT?TTCCAGTCGG?GAAACCTGTC?GTGCCAGCTG?CATTAATGAA
* * * * *TCGGCCAACG?CGCGGGGAGA?GGCGGTTTGC?GTATTGGGCG?CTCTTCCGCT
4200
* * * * *TCCTCGCTCA?CTGACTCGCT?GCGCTCGGTC?GTTCGGCTGC?GGCGAGCGGT
* * * * *ATCAGCTCAC?TCAAAGGCGG?TAATACGGTT?ATCCACAGAA?TCAGGGGATA
4300
* * * * *ACGCAGGAAA?GAACATGTGA?GCAAAAGGCC?AGCAAAAGGC?CAGGAACCGT
* * * * *AAAAAGGCCG?CGTTGCTGGC?GTTTTTCCAT?AGGCTCCGCC?CCCCTGACGA
4400
* * * * * GCATCACAAA?AATCGACGCT?CAAGTCAGAG?GTGGCGAAAC?CCGACAGGAC
* * * * *TATAAAGATA?CCAGGCGTTT?CCCCCTGGAA?GCTCCCTCGT?GCGCTCTCCT
4500
* * * * *GTTCCGACCC?TGCCGCTTAC?CGGATACCTG?TCCGCCTTTC?TCCCTTCGGG
* * * * *AAGCGTGGCG?CTTTCTCAAT?GCTCACGCTG?TAGGTATCTC?AGTTCGGTGT
4600
* * * * *AGGTCGTTCG?CTCCAAGCTG?GGCTGTGTGC?ACGAACCCCC?CGTTCAGCCC
* * * * *GACCGCTGCG?CCTTATCCGG?TAACTATCGT?CTTGAGTCCA?ACCCGGTAAG
4700
* * * * *ACACGACTTA?TCGCCACTGG?CAGCAGCCAC?TGGTAACAGG?ATTAGCAGAG
* * * * *CGAGGTATGT?AGGCGGTGCT?ACAGAGTTGT?TGAAGTGGTG?GCCTAACTAC
4800
* * * * *GGCTACACTA?GAAGGACAGT?ATTTGGTATC?TGCGCTCTGC?TGAAGCCAGT
* * * * *TACCTTCGGA?AAAAGAGTTG?GTAGCTCTTG?ATCCGGCAAA?CAAACCACCG
4900
* * * * *CTGGTAGCGG?TGGTTTTTTT?GTTTGCAAGC?AGCAGATTAC?GCGCAGAAAA
* * * * *AAAGGATCTC?AAGAAGATCC?TTTGATCTTT?TCTACGGGGT?CTGACGCTCA
5000
* * * * *GTGGAACGAA?AACTCACGTT?AAGGGATTTT?GGTCATGAGA?TTATCAAAAA
* * * * *GGATCTTCAC?CTAGATCCTT?TTAAATTAAA?AATGAAGTTT?TAAATCAATC
5100
* * * * *TAAAGTATAT?ATGAGTAAAC?TTGGTCTGAC?AGTTACCAAT?GCTTAATCAG
* * * * *TGAGGCACCT?ATCTCAGCGA?TCTGTCTATT?TCGTTCATCC?ATAGTTGCCT
5200
* * * * *GACTCCCCGT?CGTGTAGATA?ACTACGATAC?GGGAGGGCTT?ACCATCTGGC
* * * * *CCCAGTGCTG?CAATGATACC?GCGAGACCCA?CGCTCACCGG?CTCCAGATTT
5300
* * * * *ATCAGCAATA?AACCAGCCAG?CCGGAAGGGC?CGAGCGCAGA?AGTGGTCCTG
* * * * *CAACTTTATC?CGCCTCCATC?CAGTCTATTA?ATTGTTGCCG?GGAAGCTAGA
5400
* * * * *GTAAGTAGTT?CGCCAGTTAA?TAGTTTGCGC?AACGTTGTTG?CCATTGCTAC
* * * * *AGGCATCGTG?GTGTCACGCT?CGTCGTTTGG?TATGGCTTCA?TTCAGCTCCG
5500
* * * * *GTTCCCAACG?ATCAAGGCGA?GTTACATGAT?CCCCCATGTT?GTGCAAAAAA
* * * * *GCGGTTAGCT?CCTTCGGTCC?TCCGATCGTT?GTCAGAAGTA?AGTTGGCCGC
5600
* * * * *AGTGTTATCA?CTCATGGTTA?TGGCAGCACT?GCATAATTCT?CTTACTGTCA
* * * * *TGCCATCCGT?AAGATGCTTT?TCTGTGACTG?GTGAGTACTC?AACCAAGTCA
5700
* * * * *TTCTGAGAAT?AGTGTATGCG?GCGACCGAGT?TGCTCTTGCC?CGGCGTCAAT
* * * * *ACGGGATAAT?ACCGCGCCAC?ATAGCAGAAC?TTTAAAAGTG?CTCATCATTG
5800
* * * * *GAAAACGTTC?TTCGGGGCGA?AAACTCTCAA?GGATCTTACC?GCTGTTGAGA
* * * * *TCCAGTTCGA?TGTAACCCAC?TCGTGCACCC?AACTGATCTT?CAGCATCTTT
5900
* * * * *TACTTTCACC?AGCGTTTCTG?GGTGAGCAAA?AACAGGAAGG?CAAAATGCCG
* * * * *CAAAAAAGGG?AATAAGGGCG?ACACGGAAAT?GTTGAATACT?CATACTCTTC
6000
* * * * *CTTTTTCAAT?ATTATTGAAG?CATTTATCAG?GGTTATTGTC?TCATGAGCGG
* * * * *ATACATATTT?GAATGTATTT?AGAAAAATAA?ACAAATAGGG?GTTCCGCGCA
* *CATTTCCCCG?AAAAGTGCCA?CCTGACGTC
Among the plasmid pE/C sequence dna fragment of coding Chinese erythropoietin measure utilize the Sequenase test kit (United States Biochemical Inc.USA), is a template with the denatured double stranded dna, with α-
35S-dATP is a mark, adopts the two deoxidation cessation method of Sanger to measure recombinant plasmid pE/C Chinese erythropoietin coding region dna sequence dna, and measurement result sees Table 2.
The sequence of the dna fragmentation of coding Chinese erythropoietin among the table 2. plasmid pE/C
ATGGGGGTG?CACGAATGTCCTGCCTGGCT?GTGGCTTCTC?CTGTCCCTGC?TGTCGCTCCC?TCTGGGCCTCCCAGTCCTGG?GCGCCCCACC?ACGCCTCATC?TGTGACAGCC?GAGTCCTGGAGAGGTACCTC?TTGGAGGCCA?AGGAGGCCGA?GAATATCACG?ACGGGCTGTGCTGAACACTG?CAGCTTGAAT?GAGAATATCA?CTGTCCCAGA?CACCAAAGTTAATITCTATG?CCTGGAAGAG?GATCGAGGTC?GGGCAGCAGG?CCGTAGAAGTCTGGCAGGGC?CTGGCCCTGC?TGTCGGAAGC?TGTCCTGCGG?CCCCAGGCCCTGTTGGTCAA?CTCTICCCAG?CCGTGGGAGC?CCCTGCAGCT?GCATGTGGATAAAGCCGTCA?GTGGCCTTCG?CAGCCTCACC?ACTCTGCTTC?GGGCTCTGCGAGCCCAGAAG?GAAGCCATCT?CCCCTCCAGA?TGCGGCCTCA?GCTGCTCCACTCCGAACAAT?CACTGCTGAC?ACTTTCCGCA?AACTCTTCCG?AGTCTACTCCAATTTCCTCC?GGGGAAAGCT?GAAGCTGTAC?ACAGGGGAGG?CCTGCAGGACAGGGGACAGA
According to the dna sequence dna of measuring, the maturation protein amino acid composition sequence of deriving Chinese's erythropoietin sees Table 3..
The amino acid composition sequence of table 3. Chinese erythropoietin maturation protein:
APP?RLICDSRVLE?RYLLEAKEAENITTGCAEHC?SLNENITVPD?TKVNFYAWKR?MEVGQQAVEV?WQGLALLSEAVLRGQALLVN?SSQPWEPLQL?HVDKAVSGLR?SLTTLLRALR?AQKEAISPPDAASAAPLRTI?TADFFRKLFR?VYSNFLRGKL?KLYTGEACRT?GDR
3. the structure of expression cell line
Host cell is Chinese hamster ovary cell (the CHO dhfr of Tetrahydrofolate dehydrogenase defective type available from American Type Culture Collecti (ATCC)
-).With this cell cultures in the 100mm culture dish, treat that cell covered with to 50～60% o'clock,, add by 5ml serum free medium, 10ug pE/C, 10ug pDHFR (see figure 2) with serum free medium drip washing cell, the transfection mixed solution that 60ug lipofectin forms was cultivated 4 hours for 37 ℃.The sucking-off substratum adds the F12 substratum that contains 10% foetal calf serum, 37 ℃ of overnight incubation.In the DMEM that contains penicillin, Streptomycin sulphate and 10% foetal calf serum, cultivate subsequently, with trypsin digestion cell, by dilution in 1: 5, in substratum, add MTX to final concentration be 1nM, continue to cultivate and occurred to resistance clone in 10～14 days.With the cell that the trysinization resistance clone is turned out, dilution in 1: 5 raises MTX concentration by 1nM → 5nM → 25nM → 100nM → 200nM → 1000nM subsequently gradually, the screening resistance clone.The resistance clone that will occur in containing 200nM MTX substratum is incubated in the 100mm culture dish, by dilution in 1: 500, continues to cultivate 3-5 days, reaches 2～4mm until the cell clone diameter.Utilize enzyme-linked immunosorbent assay to confirm that resulting cell can the expressing human erythropoietin.
Caption:
Fig. 1. the structural representation of plasmid pE/C
Fig. 2. the sub-1-656 tripartite leader[of the structural representation pE/C plasmid structure C MV promotor 209-864T7 promotor 865-883SP6 promotor 138-1645 people EPO gene 890-1520SV40 promotor 2674-2799 neomycin resistance gene 2805-3599SV40 polyadenylic acid tailing 3603-3812PDHFR plasmid structure gland virus stage starting 657-945 multiple clone site 956-1056 dihydrofolate reductase gene 1080-1678SV40 polyadenylic acid tailing 1856-2012 of plasmid pDHFR
Claims (6)
1. erythropoietin albumen, it is characterized in that: (1) SDS-PAGE apparent molecular weight is that 36～45KD (2) peptide chain portion is APP RLICDSRVLE RYLLEAKEAENITTGCAEHC SLNFNITVPD TKVNFYAWKR MEVGQQAVEV WQGLALLSEAVLRGQALLVN SSQPWEPLQL HVDKAVSGLR SLTTLLRALR AQKEAISPPDAASAAPLRTI TADFFRKLFR VYSNFLRGKL KLYTGEACRT GDR
(3) the 113rd amino acids residues are Arg
(4), be a glycoprotein by expressing cho cell.
2. the derivative of erythropoietin protein is characterized in that: be made up of all or part of aminoacid sequence in the claim 1, have the erythropoietin activity, comprise glycosylation form and non-glycosylated form.
3. the dna molecular of the erythropoietin of encoding is characterized in that:
( 1 ) ： ATGGGGGTG CACGAATGTCCTGCCTGGCT GTGGCTTCTC CTGTCCCTGC TGTCGCTCCC TCTGGGCCTCCCAGTCCTGG GCGCCCCACC ACGCCTCATC TGTGACAGCC GAGTCCTGGAGAGGTACCTC TTGGAGGCCA AGGAGGCCGA GAATATCACG ACGGGCTGTGCTGAACACTG CAGCTTGAAT GAGAATATCA CTGTCCCAGA CACCAAAGTTAATTTCTATG CCTGGAAGAG GATGGAGGTC GGGCAGCAGG CCGTAGAAGTCTGGCAGGCC CTGGCCCTGC TGTCGGAACC TGTCCTGCGG GGCCAGGCCCTGTTGGTCAA CTCTTCCCAG CCGTGGGAGC CCCTGCAGCT GCATGTGGATAAAGCCGTCA GTGGCCTTCG CAGCCTCACC ACTCTGCTTC GGGCTCTGCGAGCCCAGAAG GAAGCCATCT CCCCTCCAGA TGCGGCCTCA GCTGCTCCACTCCGAACAAT CACTGCTGAC ACTTTCCGCA AACTCTTCCG AGTCTACTCCAATTTCCTCC GGGGAAAGCT GAAGCTGTAC ACAGGGGAGG CCTGCAGGACAGGGGACAGA
(2) the 418th bit bases are C
4. new recombinant plasmid pE/C is characterized in that:
(1) this plasmid is by 6079 based compositions in the table 1.
(2) 899-1477 base is dna molecular in the claim 3 in this plasmid
(3) Chinese hamster ovary cell of this plasmid and plasmid pDHFR cotransfection Tetrahydrofolate dehydrogenase defective type can be used for expressing the erythropoietin in the claim 1.The plasmid pDHFR here is available from Invitrogen.
5. the genetically engineered cell strain of expressing human erythropoietin is characterized in that:
(1) obtains by plasmid pE/C in the claim 4 and plasmid pDHFR cotransfection Tetrahydrofolate dehydrogenase defective type Chinese hamster ovary cell.The plasmid pDHFR here is available from Invitrogen, and Chinese hamster ovary cell is available from American Type Culture Collecti.
(2) through cultivating the erythropoietin that to express in the claim 1.
(3) this cell strain reaches 10000U/ml.10 to the expression amount of the erythropoietin in the claim 1
6Cell.
6. one kind has the active medicine of erythropoietin, it is characterized in that: the albumen in the claim 1 or 2 is as all or part of active ingredient of this medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96115004 CN1143116A (en) | 1995-04-14 | 1996-01-05 | New human erythropoietin |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95110171.4 | 1995-04-14 | ||
| CN 95110171 CN1118008A (en) | 1995-04-14 | 1995-04-14 | Erythropoietin for human |
| CN 96115004 CN1143116A (en) | 1995-04-14 | 1996-01-05 | New human erythropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1143116A true CN1143116A (en) | 1997-02-19 |
Family
ID=25743741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 96115004 Pending CN1143116A (en) | 1995-04-14 | 1996-01-05 | New human erythropoietin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1143116A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101044239B (en) * | 2002-12-23 | 2010-12-08 | 布里斯托尔-迈尔斯斯奎布公司 | Mammalian cell culture process for protein production |
-
1996
- 1996-01-05 CN CN 96115004 patent/CN1143116A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101044239B (en) * | 2002-12-23 | 2010-12-08 | 布里斯托尔-迈尔斯斯奎布公司 | Mammalian cell culture process for protein production |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102759317B1 (en) | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated viruses | |
| AU2014374516B2 (en) | Construct and sequence for enhanced gene expression | |
| CN109415429B (en) | HERV-E reactive T cell receptors and methods of use | |
| DK2185696T3 (en) | Cells genetically modified to include pancreatic glucokinase, and uses thereof | |
| CN1209436A (en) | Human semaphorin L(H-SemaL) and corresponding semaphorins in other species | |
| CN114324864A (en) | IgM and IgG double-detection immunochromatographic test paper for varicella-zoster virus and application thereof | |
| KR101274790B1 (en) | Cell line for producing coronaviruses | |
| AU2022214501B2 (en) | Pharmaceutical composition for treating liver diseases using ssu72 | |
| KR20200086902A (en) | A vector for monitoring differentiation of neural cells and method for monitoring the differentiation into neural cells using the same | |
| KR102441384B1 (en) | Screening method for skin lightening substances | |
| CN114324878A (en) | Fluorescence-labeled varicella-zoster virus immunochromatography detection test paper and application thereof | |
| CN1143116A (en) | New human erythropoietin | |
| CN1118008A (en) | Erythropoietin for human | |
| CN103864902B (en) | A kind of bivalent DNA vaccine connection peptides and application thereof | |
| CN1168413A (en) | Erythropoietin | |
| CN113652412A (en) | Method for preparing restriction enzyme products | |
| US20040076636A1 (en) | HIV immunogenic complexes | |
| CN110115770B (en) | A new target for the prevention and treatment of viral hepatitis C and its CRISPR-Cas9 targeting system and application | |
| CN114480398A (en) | siRNA and application thereof in preparing medicine for improving and/or treating leucoderma | |
| SALIWANCHIK | Yen et al.(43) Pub. Date: Feb. 9, 2006 | |
| CN115429796A (en) | Liluzole targeted treatment of Wolfram syndrome | |
| CN110312803B (en) | Compositions and methods for editing nucleic acid sequences | |
| CN106519005B (en) | Phosphorylated NFAT3 mutant and its application | |
| CN114457113B (en) | Method for inhibiting haploid embryonic stem cell doubling | |
| CN111560392B (en) | miRNA expression vector and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |